34LA Stock Overview
Alpine Immune Sciences, Inc. operates as clinical-stage biopharmaceutical company.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Alpine Immune Sciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$36.80 |
52 Week High | US$38.20 |
52 Week Low | US$6.15 |
Beta | 1.13 |
1 Month Change | 22.67% |
3 Month Change | 110.29% |
1 Year Change | 409.70% |
3 Year Change | 297.84% |
5 Year Change | 512.31% |
Change since IPO | 411.04% |
Recent News & Updates
Recent updates
Shareholder Returns
34LA | DE Biotechs | DE Market | |
---|---|---|---|
7D | 12.9% | 4.5% | 1.4% |
1Y | 409.7% | 34.1% | 7.5% |
Return vs Industry: 34LA exceeded the German Biotechs industry which returned 34.1% over the past year.
Return vs Market: 34LA exceeded the German Market which returned 7.5% over the past year.
Price Volatility
34LA volatility | |
---|---|
34LA Average Weekly Movement | 20.2% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 34LA's share price has been volatile over the past 3 months.
Volatility Over Time: 34LA's weekly volatility has increased from 13% to 20% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 142 | Mitch Gold | https://www.alpineimmunesciences.com |
Alpine Immune Sciences, Inc. operates as clinical-stage biopharmaceutical company. It focuses on discovery and development of immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company’s product pipeline includes Povetacicept, a dual B cell cytokine antagonist, that is in Phase 2 clinical stage for multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways, that is in preclinical trial for treatment of systemic lupus erythematosus.
Alpine Immune Sciences, Inc. Fundamentals Summary
34LA fundamental statistics | |
---|---|
Market cap | €2.39b |
Earnings (TTM) | -€29.78m |
Revenue (TTM) | €54.48m |
43.8x
P/S Ratio-80.1x
P/E RatioIs 34LA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
34LA income statement (TTM) | |
---|---|
Revenue | US$58.88m |
Cost of Revenue | US$80.90m |
Gross Profit | -US$22.03m |
Other Expenses | US$10.16m |
Earnings | -US$32.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.49 |
Gross Margin | -37.41% |
Net Profit Margin | -54.66% |
Debt/Equity Ratio | 0% |
How did 34LA perform over the long term?
See historical performance and comparison